ORIGINAL
Carfilzomib and dexamethasone in multiple myeloma patients refractory to anti-CD38 monoclonal antibodies
2024 年 14 巻 5 号 p. 42-46
詳細
2024 年 14 巻 5 号 p. 42-46
Objective: CD38 monoclonal antibodies have improved the prognosis of multiple myeloma (MM) patients. However, there is limited evidence for the treatment of MM patients who are refractory to CD38 monoclonal antibodies (CD38mAb). Carfilzomib (CFZ) is a second-generation proteasome inhibitor showing clinical efficacy in relapse and refractory MM patients without previous exposure to CD38mAb. The current study investigated the role of CFZ in CD38mAb refractory MM patients.
Methods: MM patients who became refractory to anti-CD38 antibodies and were subsequently treated with CFZ and dexamethasone (Kd) were retrospectively analyzed for progression free survival (PFS), overall survival (OS) and factors affecting PFS and OS.
Patients: Twelve MM patients, who were diagnosed between year 2002 and 2021, became refractory to CD38mAb-containing regimens, and were subsequently treated with at least one cycle of Kd in Kumamoto University Hospital were enrolled.
Results: The overall response rate of Kd was 58.3%, while median progression-free survival and overall survival were 10.8 months and 29.4 months respectively. The presence of high-risk cytogenetic abnormalities (HRCA) had an impact in PFS, while refractoriness to pomalidomide affected OS.
Conclusion: Kd can be a feasible therapeutic option for CD38 antibody-refractory myeloma patients without HRCA.
